Omega Funds leads $35M Se­ries A to fu­el At­ten­u­a's cough pro­gram, set for proof-of-con­cept this year

As At­ten­ua con­tin­ues to de­vel­op its lead pro­gram for chron­ic cough, it will be do­ing so with $35 mil­lion in the bank and un­der the lead­er­ship of a new CEO.

In con­junc­tion with the Se­ries A fund­ing — led by Omega Funds with par­tic­i­pa­tion from a syn­di­cate that in­cludes Abing­worth, Or­biMed and Red­mile Group — Michael Kitt has tak­en the helm from founder Jing Liang. Kitt had pre­vi­ous­ly served as CMO at a few biotechs, most re­cent­ly at an­oth­er cough drug de­vel­op­er, Af­fer­ent Phar­ma­ceu­ti­cals, pri­or to its ac­qui­si­tion by Mer­ck.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.